Pharma

Eli Lilly and Company

Articles

Primary Subject

Top Role

Jan 22, 2026

First Mention

Apr 11, 2026

Last Mention

14.09

Relevance Score

Intelligence Brief

Based on 10 articles | Generated Apr 11, 2026

Overview

Eli Lilly and Company is a major player in the pharmaceutical industry, focusing on innovative treatments for diabetes, oncology, and neurodegenerative diseases. Right now, their strategic focus on obesity and Alzheimer's treatments is crucial, as these areas represent significant unmet needs and market potential. The recent acquisition of DICE Therapeutics underscores their commitment to expanding their autoimmune portfolio.

Assets & Portfolio

Lilly owns a robust portfolio including Mounjaro (tirzepatide) for diabetes and obesity, and donanemab for Alzheimer's. They have a strong pipeline with orforglipron and survodutide leading the charge in oral obesity treatments. Their infrastructure includes advanced R&D facilities and a global manufacturing network.

Partnerships & Deals

Lilly collaborates with Boehringer Ingelheim on Jardiance, a key diabetes medication. This partnership allows them to leverage combined expertise and market reach. They also engage in strategic acquisitions, like the recent $2.4 billion purchase of DICE Therapeutics, to bolster their autoimmune and platform technology capabilities.

Pipeline & Development

Lilly's pipeline is rich with late-stage candidates like orforglipron and survodutide targeting obesity, and donanemab for Alzheimer's. The TRAILBLAZER-ALZ 3 study results are pivotal for donanemab's future. Their focus on oral obesity treatments positions them well to capture a larger patient base resistant to injections.

Competitive Position

Lilly is leading in the obesity space, with tirzepatide setting the pace against Novo Nordisk's GLP-1s. However, the surprise CRL for retatrutide shows vulnerabilities. In Alzheimer's, they are neck-and-neck with Roche, both delaying FDA submissions to strengthen their cases.

Technology & Innovation

Lilly is forward-looking, integrating cutting-edge technology into their drug discovery and development processes. Their investment in platform technologies through DICE Therapeutics suggests a focus on innovative approaches and automation in R&D. They are not stuck in legacy systems.

Growth Outlook

Lilly is on a rapid growth trajectory, driven by the success of Mounjaro and a promising late-stage pipeline. The strategic focus on high-demand areas like obesity and Alzheimer's should sustain momentum. However, regulatory hurdles like the CRL for retatrutide could pose risks.

Industry Trend Fit

Lilly's emphasis on oral obesity treatments aligns with the industry's shift towards patient-friendly, non-injection therapies. They are well-positioned to benefit from trends in AI-driven drug discovery and value-based care models. Their pricing strategies will be tested by IRA reforms and CMS negotiations.

Coverage Timeline

April 2026

FDA Accelerated Approval Crackdown Shifts the Landscape for Aduhelm and Alzheimer's Pipeline Policy Mentioned

Apr 11, 2026

Eli Lilly’s donanemab and Roche’s gantenerumab have delayed FDA submissions to bulk up their dossiers.

Novo Nordisk CFO Departure Signals Financial Reset After $40B Market Cap Surge on GLP-1 Boom People Competitor

Apr 11, 2026

Novo faces the classic 'what’s next?' problem, racing to keep pace with Eli Lilly’s tirzepatide across new obesity and NASH indications.

Eli Lilly's $2.4 Billion DICE Therapeutics Bet: Pipeline Risk, Platform Ambition, and Autoimmune Expansion Deals Primary Subject

Apr 9, 2026

When Lilly revealed its $2.4 billion acquisition of DICE Therapeutics in June 2023, the 40% premium to DICE’s trailing share price made headlines.

March 2026

The Week in Pharma: Lilly Bets $2.5B on Alzheimer’s, Pfizer Shifts Oncology Gears, Policy Upheaval Hits Drug Discovery The Week Primary Subject

Mar 14, 2026

Eli Lilly finally revealed the headline results from its pivotal Phase 3 TRAILBLAZER-ALZ 3 study.

Lilly’s Mounjaro Pricing Strategy: Gross-to-Net Math Behind Market Dominance Money Primary Subject

Mar 6, 2026

Eli Lilly didn’t land on Mounjaro’s $1,023 monthly list price by accident.

February 2026

Weekly Pharma Roundup: Merck's $11B Bet, FDA Pushback, and Earnings Surprises The Week Primary Subject

Feb 21, 2026

Eli Lilly got hit with a surprise Complete Response Letter (CRL) from the FDA for its much-hyped obesity biologic, retatrutide.

Late-Stage Obesity Drugs Beyond GLP-1s: Orforglipron, Survodutide, and the Oral Alternatives That Could Reshape Pricing Pipeline Primary Subject

Feb 18, 2026

In the race for oral obesity treatments, Eli Lilly’s orforglipron leads the pack.

IRA Price Negotiation Year One: What the Numbers Reveal About CMS, Drugmakers, and the Real Deals Policy Mentioned

Feb 5, 2026

The reality: these drugs were uniquely vulnerable.

January 2026

Obesity Pipeline Beyond GLP‑1s: Orforglipron, Survodutide, and the Oral Disruptors Pipeline Primary Subject

Jan 27, 2026

For Lilly, orforglipron could reach the millions who simply refuse injections.

IRA Price Negotiation Year One: Who Blinked, Who Balked, and What's Next for Big Ticket Drugs Policy Mentioned

Jan 22, 2026

Jardiance (Boehringer/Lilly) was among the list of drugs up for negotiation.